Hospira, the sole U.S. maker of a key execution drug, has decided to permanently halt production of the drug, which could lead many states to face delay in carrying out the death penalty.
WSJ.com: What's News US, Wall Street Journal
Fri, 01/21/2011 - 9:59am
Hospira, the sole U.S. maker of a key execution drug, has decided to permanently halt production of the drug, which could lead many states to face delay in carrying out the death penalty.